(Press-News.org)
UVA Health researchers have identified a potential treatment to prevent severe COVID-19 in patients at great risk.
The new research from UVA’s Jie Sun, PhD, and colleagues suggests a way to protect patients with obesity or diabetes from the runaway inflammation and dangerous blood sugar spikes that COVID-19 can cause. Such patients are at high risk for severe COVID-19, and, with the effectiveness of existing COVID treatments waning, new treatment options are needed urgently.
“Our work has uncovered a metabolic pathway that concurrently modulates COVID-19 inflammation, lung recovery and host metabolic health, and suggests a potentially viable therapeutic agent that may be combined with existing anti-viral agents to treat severe COVID-19 in patients with underlying metabolic disease,” said Sun, of UVA’s Division of Infectious Diseases and International Health and UVA’s Carter Immunology Center. “We are hoping this study could spur strong interests for clinical trials to prevent or treat severe viral infections including COVID-19 in diabetic and/or obese individuals using a second-generation insulin sensitizer.”
Preventing Severe COVID-19
Sun’s approach seeks to prevent severe COVID-19 by targeting the carrier of fuel to mitochondria, the powerhouses of our cells. Sun and his team found that reducing the activity of this carrier protected obese lab mice from severe illness caused by influenza and COVID-19. The reduction of the fuel supply simultaneously reduced harmful inflammation and promoted metabolic health. It also helped prevent harmful blood sugar spikes associated with COVID-19 and promoted lung recovery after COVID-19 and influenza pneumonia.
The researchers noted that their approach “synergized” with the antiviral component of Paxlovid, nirmatrelvir, to “markedly” reduce mortality in the lab mice. That suggests it may be possible to use an insulin-sensitizing drug to obtain similar results in human patients with COVID-19.
“We know that steroids are effective in severe COVID-19, but these drugs have side effects like elevated blood glucose that make their use more complicated in obese and diabetic patients,” said study co-author Jeffrey Sturek, MD, PhD, a UVA pulmonary and critical care physician-scientist specializing in COVID-19 disease. “The really exciting part about this pathway is the ability to treat both inflammation as well as altered glucose metabolism.”
To assess the potential benefits in humans, the scientists tested their approach using human lung tissue samples. They were pleased to see the drug diminished cellular inflammation – a promising sign, though more testing will be needed.
Based on the results, the UVA scientists and Cirius Therapeutics – the maker of the insulin-sensitizing drug the scientists used – are planning a clinical trial testing the drug in human patients with COVID-19. Cirius Therapeutics is developing the drug to treat liver damage in patients with non-alcoholic fatty liver disease. The drug works through a recently identified mechanism to reprogram mitochondrial metabolism and has an “outstanding” safety profile, the researchers note in a scientific paper outlining their findings.
That leaves the UVA scientists hopeful that their new research could make a real difference for people at high risk for severe COVID-19.
“Diabetes increases COVID-19 severity, and, conversely, COVID-19 can lead to blood glucose rise,” Sun said. “Our work suggests that we can use a second-generation Thiazolidinedione drug to break the network of SARS-CoV-2 infection, hyperglycemia [blood glucose rise] and hyper-inflammation, all factors known to drive COVID-19 pathophysiology.”
Findings Published
The researchers have published their findings in the journal Science Immunology. The team consisted of Bibo Zhu, Xiaoqin Wei, Harish Narasimhan, Wei Qian, Ruixuan Zhang, In Su Cheon, Yue Wu, Chaofan Li, Russell G. Jones, Mark H. Kaplan, Robert A. Vassallo, Thomas J. Braciale, Lindsay Somerville, Jerry R. Colca, Akhilesh Pandey, Patrick E. H. Jackson, Barbara J. Mann, Connie M. Krawczyk, Jeffrey M. Sturek and Sun. Sun is a consultant for TeneoFour; a full list of the authors’ disclosures is included in the paper. UVA is seeking a patent on the use of the drug, MSDC-0602K, and combinations in treating severe viral pneumonia.
The research was supported by the National Institutes of Health, grants AI147394, AG069264, AI 112844 and AI 154598 and Interdisciplinary Training Program in Immunology T32 AI007496.
To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog at http://makingofmedicine.virginia.edu.
END
With the aid of some sea slugs, University of Nebraska–Lincoln chemists have discovered that one of the smallest conceivable tweaks to a biomolecule can elicit one of the grandest conceivable consequences: directing the activation of neurons.
Their discovery came from investigating peptides, the short chains of amino acids that can transmit signals among cells, including neurons, while populating the central nervous systems and bloodstreams of most animals. Like many other molecules, an amino acid in a peptide can adopt one of two forms that feature the same atoms, with the same connectivity, but in mirror-image orientations: L and ...
OAK BROOK, Ill. – In a study of over a million women, digital breast tomosynthesis (DBT) showed improved breast cancer screening outcomes over screening with standard digital mammography alone. The results of the study were published in Radiology, a journal of the Radiological Society of North America (RSNA).
Breast cancer is the most common cancer among women in the United States. While breast cancer mortality has been on the decline since the late 1980s due to improvements in early detection and treatment, it still remains the leading cause of cancer death among women.
The five-year relative survival rate of breast cancer when it is detected early in its localized ...
OAK BROOK, Ill. – Regions of the U.S. with an extreme level of socioeconomic disadvantage were less likely to have access to accredited medical imaging facilities and centers of excellence, according to a research letter published in Radiology, a journal of the Radiological Society of North America (RSNA).
Higher proportions of the disadvantaged zip codes were located in the rural southern portion of the U.S. A lack of access to high-quality imaging facilities has the potential to lead to delayed or missed diagnoses, further exacerbating the health disparities experienced by people who live in disadvantaged communities.
“Patients ...
A recent study in the Journal of Biological Chemistry has revealed the secret behind an evolutionary marvel: a bacteriophage with an extremely long tail. This extraordinary tail is part of a bacteriophage that lives in inhospitable hot springs and preys on some of the toughest bacteria on the planet.
Bacteriophages are a group of viruses that infect and replicate in bacteria and are the most common and diverse things on Earth.
“Bacteriophages, or phages for short, are everywhere that bacteria are, including the dirt and water around you and in your own body’s microbial ecosystem as well,” said Emily Agnello, a graduate student at the University of ...
A clinical study by researchers at Karolinska Institutet and Karolinska University Hospital in Sweden shows that the hunger hormone ghrelin can increase the heart’s pump capacity in patients with heart failure. The results have been published in the European Heart Journal.
Millions of people worldwide live with heart failure, a condition in which the pump function of the heart is reduced, such as after a myocardial infarction or angina. In heart failure, the heart muscle is weakened, leaving the heart unable to pump the amount of blood needed to provide the body with sufficient oxygen ...
Peru’s first great empire, the Wari, stretched for more than a thousand miles over the Andes Mountains and along the coast from 600-1000 CE. The pottery they left behind gives archaeologists clues as to how the empire functioned. In a new study in the Journal of Archaeological Science: Reports, researchers showed that rather than using “official” Wari pottery imported from the capital, potters across the empire were creating their own ceramics, decorated to emulate the traditional Wari style. To figure it out, the scientists analyzed the pottery’s chemical make-up, with help from laser beams.
“In this study, ...
Most animals can quickly transition from walking to jumping to crawling to swimming if needed without reconfiguring or making major adjustments.
Most robots cannot. But researchers at Carnegie Mellon University have created soft robots that can seamlessly shift from walking to swimming, for example, or crawling to rolling.
"We were inspired by nature to develop a robot that can perform different tasks and adapt to its environment without adding actuators or complexity," said Dinesh K. Patel, a post-doctoral fellow in the Morphing Matter Lab in the School of Computer Science's Human-Computer Interaction Institute. "Our bistable actuator ...
Scientists to retrofit large shipping vessels with ultramodern sails in efforts to cut carbon emissions
University of Southampton initiative will investigate how modern vessels perform on the ocean when fitted with the wing-sails
Funding from Innovate UK to investigate the potential of the technology and decarbonise the UK’s maritime sector
SHIPS of the future could once again be powered by wind if a pioneering project which retrofits large vessels with ultramodern wing-sails proves successful in cutting carbon emissions.
Scientists ...
Shixin Liu receives the Vilcek Prize for Creative Promise in Biomedical Science for developing cutting-edge biophysical tools to directly visualize and understand the physiological function of nanometer-scale biomolecular machines such as those that carry out genome replication and gene transcription.
The Vilcek Prize for Creative Promise is a $50,000 prize awarded annually by the Vilcek Foundation as part of its prizes program. Awarded annually since 2006, the Vilcek Foundation prizes recognize and celebrate immigrant contributions to scientific research and discovery, and to artistic and cultural advancement in the United States. In addition ...
National Institutes of Health researchers compared a new genetic animal model of Down syndrome to the standard model and found the updated version to be enhanced. The new mouse model shows milder cognitive traits compared to a previously studied Down syndrome mouse model. The results of this study, published in Biological Psychiatry, may help researchers develop more precise treatments to improve cognition in people with Down syndrome.
Scientists found that the new mouse model, known as Ts66Yah, had memory difficulties and behavior traits, but the symptoms were not as severe as seen with the ...
